US 12,448,413 B2
HSP70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen presenting cell
Tomoya Miyakawa, Tokyo (JP); Masaaki Oka, Yamaguchi (JP); Shoichi Hazama, Yamaguchi (JP); Koji Tamada, Yamaguchi (JP); and Keiko Udaka, Kochi (JP)
Assigned to NEC CORPORATION, Tokyo (JP)
Filed by NEC CORPORATION, Tokyo (JP)
Filed on Mar. 11, 2022, as Appl. No. 17/693,046.
Application 17/693,046 is a division of application No. 16/715,758, filed on Dec. 16, 2019, granted, now 11,304,997.
Application 16/715,758 is a division of application No. 15/516,918, granted, now 10,537,626, previously published as PCT/JP2015/078504, filed on Oct. 7, 2015.
Claims priority of application No. 2014-206730 (JP), filed on Oct. 7, 2014.
Prior Publication US 2022/0193213 A1, Jun. 23, 2022
Int. Cl. C07K 16/00 (2006.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01); A61K 40/19 (2025.01); A61K 40/24 (2025.01); A61K 40/42 (2025.01); A61K 47/50 (2017.01); C07K 7/06 (2006.01); C12N 15/09 (2006.01)
CPC C07K 7/06 (2013.01) [A61K 38/00 (2013.01); A61K 40/19 (2025.01); A61K 40/24 (2025.01); A61K 40/4262 (2025.01); A61K 47/50 (2017.08); C12N 15/09 (2013.01); A61K 2039/545 (2013.01); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05); A61K 2239/53 (2023.05)] 6 Claims
 
1. A pharmaceutical composition for inducing an immune response in a subject suffering from cancer, comprising a peptide consisting of a variant of the amino acid sequence of SEQ ID NO: 7,
wherein the variant consists of nine amino acid residues, and wherein in the amino acid sequence of the variant, the amino acid corresponding to position 2 of the amino acid sequence of SEQ ID NO: 7 is substituted by tyrosine, phenylalanine, methionine, tryptophan, valine, leucine, or glutamine; and/or the amino acid at the C-terminal is substituted by phenylalanine, leucine, tryptophan, methionine, or valine.